-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

Benzinga·11/02/2026 17:46:03
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $779 to $855.